Mehta Analysis: What Can Tesla Teach Pharma?
Health Breakthroughs Demand Regulatory Revolution
Executive Summary
The transformation of the automotive world has many lessons for biopharma, especially on the regulatory front, believes Viren Mehta of Mehta Partners.
You may also be interested in...
Mehta Analysis: Welcome to BioPharma 2.0
Viren Mehta of Mehta Partners LLC ponders what the approval of Novartis gene therapy Zolgensma foreshadows, in terms of future therapies and pricing.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.
Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish
As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses.